Bone marrow aspirate concentrate versus platelet-rich plasma for treating knee osteoarthritis: a one-year non-randomized retrospective comparative study

BMC Musculoskeletal Disorders

Carlos Lumbao¹  Riam Shammaa²  Natasha Salame³  Moutih Rafei⁴  Abed El-Hakim El-Kadiry⁵ 

[1] Canadian Centres for Regenerative Therapy, Toronto, ON, Canada;Canadian Centres for Regenerative Therapy, Toronto, ON, Canada;Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada;Department of Biomedical Sciences, Université de Montréal, Montreal, QC, Canada;Department of Pharmacology and Physiology, Université de Montréal, Montreal, QC, Canada;Department of Microbiology, Infectious Diseases and Immunology, Université de Montréal, Montreal, QC, Canada;Molecular Biology Program, Université de Montréal, Montreal, QC, Canada;Department of Microbiology and Immunology, McGill University, Montreal, QC, Canada;Laboratory of Thrombosis and Hemostasis, Montreal Heart Institute, Research Center, Montreal, QC, Canada;Department of Biomedical Sciences, Université de Montréal, Montreal, QC, Canada;

关键词: Knee;    Osteoarthritis;    Bone marrow aspirate concentrate;    Platelet-rich plasma;    Mesenchymal stromal cells;    Visual analogue scale;    Knee injury and osteoarthritis outcome score;    Western Ontario and McMaster universities arthritis index;   

DOI  :  10.1186/s12891-021-04910-5

来源: Springer

【 摘 要 】

BackgroundKnee osteoarthritis (OA) is a debilitating condition affecting human body biomechanics and quality of life. Current standard care for knee OA leads to trivial improvement and entails multiple adverse effects or complications. Recently, investigational cell therapies injected intra-articularly, such as bone marrow aspirate concentrate (BMAC) and platelet-rich plasma (PRP), have shown safety and therapeutic potency providing patients with pain relief. In the current retrospective comparative study, we investigated the differences in pain and functional improvements in patients with symptomatic knee OA receiving intra-articular injections of BMAC vs PRP.MethodsPain and functionality scores were measured at baseline and at different time points post-injection over 12 months, using 3 self-administered, clinically validated questionnaires: the visual analogue scale (VAS) for assessing pain intensity, the knee injury and osteoarthritis outcome score (KOOS) for evaluating functionality and knee-related quality of life, and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) for evaluating physical function. The repeated-measures general linear model with Sidak test for pairwise comparisons was used to investigate the influence of the treatment on the score evolution within groups (between baseline and each time point) and between groups (overall).ResultsThe BMAC group (n = 26 knees) significantly improved in VAS, KOOS, and WOMAC scores between baseline and 12 months (57.4, 75.88, and 73.95% mean score improvement, respectively). In contrast, the PRP group (n = 13 knees) witnessed nonsignificant improvement in all scores. BMAC, in comparison to PRP, induced significant improvement in outcomes by 29.38% on the VAS scale, 53.89% on the KOOS scale, and 51.71% on the WOMAC scale (P < .002, P < .01, P < .011, respectively).ConclusionsIntra-articular autologous BMAC injections are safe, effective in treating pain, and ameliorate functionality in patients with symptomatic knee OA to a greater extent than PRP injections.Graphical abstractIntra-articular autologous BMAC therapy is safe and provides more relief to patients with symptomatic knee osteoarthritis compared to PRP therapy.

【 授权许可】

CC BY